Publication: Prolonged stabilization of progressive squamous cell cancer of the cervix with interferon-α and 13-cis-retinoic acid: Report of two cases and review of the literature
Issued Date
1996-01-01
Resource Type
ISSN
09594973
Other identifier(s)
2-s2.0-10544233360
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Anti-Cancer Drugs. Vol.7, No.7 (1996), 800-804
Suggested Citation
Surintip Piamsomboon, Wichai Termrungruanglert, Andrzej P. Kudelka, Creighton L. Edwards, Ralph S. Freedman, Clifton F. Mountain, Luis Delclos, Matti S. Aapro, Louis DeCaro, Joseph Bianca, Claire F. Verschraegen, John J. Kavanagh Prolonged stabilization of progressive squamous cell cancer of the cervix with interferon-α and 13-cis-retinoic acid: Report of two cases and review of the literature. Anti-Cancer Drugs. Vol.7, No.7 (1996), 800-804. doi:10.1097/00001813-199609000-00014 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/17576
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Prolonged stabilization of progressive squamous cell cancer of the cervix with interferon-α and 13-cis-retinoic acid: Report of two cases and review of the literature
Abstract
Recurrent and metastatic cervical carcinoma has very poor prognosis, mainly because there is no effective systemic therapy which would increase the duration of survival. Biologic agents have recently been found to have activity in cervical carcinoma. The combination of interferon (IFN)-α and 13-cis-retinoic acid has additive and synergistic antitumor activity. Both have antiviral, immunoregulatory and antiangiogenic properties, and are known to modulate malignant cell differentiation and proliferation. We report two patients with recurrent squamous cell carcinoma (SCC) of the cervix who had small-volume progressive metastatic disease, and were treated with a combination of IFN-α and 13-cis-retinoic acid. The first patient had pelvic lymph node metastases and the other had lung metastases. The previously progressive diseases remained stable for a prolonged period of time, 3 and 4 years, with a good quality of life. These cases suggest the possibility of using IFN-α and 13-cis-retinoic acid as a treatment for small-volume residual disease or as postinduction therapy in patients at high risk for disease recurrence.